Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.
İlgili Semboller 1
JANX JANX
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.